Background: Vascular occlusion during hepatectomy accompanies ischemia-reperfusion (IR) injury, which can cause liver dysfunction and affect patients' outcome. Ulinastatin or urinary trypsin inhibitor (UTI), a polyvalent inhibitor of various enzymes, has been confirmed of anti-IR injury effect in recent studies. Here we performed a systematic review and meta-analysis to assess the benefits of perioperation UTI using to protect liver function in hepatectomy.

Methods: Randomized controlled trials (RCTs) evaluating UTI in hepatectomy were identified. Two independent reviewers extracted data on basic characteristics and risk of bias in the studies, and on outcomes such as alanine transaminase (ALT), aspartate transaminase (AST), and total bilirubin (TBIL) from 1 to 7 days after operation.

Results: A total of 9 RCTs including 408 UTI and 372 control participants were identified. There was no significant difference in basic characteristics such as age or sex. The majority of the patients who underwent hepatectomy had primary liver carcinoma, liver metastases and benign liver lesions. A significant improvement in liver function was associated with UTI use not only at 1 and 3 days postoperatively, but also at 7 days (all P≤0.01). However, significant heterogeneity existed between the pooled studies (all P<0.01).

Conclusions: UTI has positive protective effects against IR injury in hepatectomy. However, further highquality RCTs are needed to confirm this conclusion.

Download full-text PDF

Source
http://dx.doi.org/10.21037/apm.2020.04.28DOI Listing

Publication Analysis

Top Keywords

liver function
12
systematic review
8
randomized controlled
8
controlled trials
8
basic characteristics
8
liver
7
uti
5
perioperation ulinastatin
4
ulinastatin intervention
4
intervention protects
4

Similar Publications

Purpose: This study aims to evaluate the diagnostic value of standardized semiquantitative scoring of color Doppler ultrasound combined with liver stiffness measurement (LSM) of sound touch elastography (STE) in chronic hepatitis B (CHB) patients, providing a reference for the liver fibrosis diagnosis.

Methods: We performed ultrasound and STE on CHB patients, with liver biopsies as the benchmark. We compared the differences in ultrasound standardized semiquantitative scoring and LSM among patients with different stages of liver fibrosis, and evaluated the diagnostic efficacy of significant liver fibrosis using receiver operating characteristic (ROC) curves and the area under the ROC curve alone or in combination.

View Article and Find Full Text PDF

Longitudinal associations between metabolic dysfunction-associated steatotic liver disease (MASLD) and subclinical cardiovascular measures in Chinese children.

Am J Gastroenterol

December 2024

Department of Epidemiology/Department of Maternal, Child and Adolescent Health, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China.

Introduction: The clinical utility of metabolic dysfunction-associated steatotic liver disease (MASLD) in predicting subsequent subclinical cardiovascular damages in pediatric population remains poorly understood.

Methods: Data on 1,161 Chinese children aged 10-15 years were used to assess the longitudinal associations of MASLD with subsequent subclinical cardiovascular damages.

Results: Compared with relatively healthy children, children with MASLD had abnormal vascular and cardiac structures, along with reduced cardiac diastolic function at the 2-year follow-up.

View Article and Find Full Text PDF

Ena-bile-ing liver cancer growth.

Science

January 2025

Gastroenterology Division, Massachusetts General Hospital, Boston, MA, USA.

Bile acids differentially affect immune cell responses to liver cancer.

View Article and Find Full Text PDF

The metabolic landscape of cancer greatly influences antitumor immunity, yet it remains unclear how organ-specific metabolites in the tumor microenvironment influence immunosurveillance. We found that accumulation of primary conjugated and secondary bile acids (BAs) are metabolic features of human hepatocellular carcinoma and experimental liver cancer models. Inhibiting conjugated BA synthesis in hepatocytes through deletion of the BA-conjugating enzyme bile acid-CoA:amino acid -acyltransferase (BAAT) enhanced tumor-specific T cell responses, reduced tumor growth, and sensitized tumors to anti-programmed cell death protein 1 (anti-PD-1) immunotherapy.

View Article and Find Full Text PDF

HBV genotype A has two major subtypes, A1 (commonly in Africa) and A2 (commonly in Europe) with only 4% nucleotide differences. Individuals infected with these two subtypes appear to have different clinical manifestations and virologic features. Whether such a difference results from the virus or host has not been established.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!